PRO 140

A Smart + Strong Site
Subscribe to:
POZ magazine
AIDS virusPRO 140 belongs to a class of anti-HIV drugs called Entry Inhibitors (including Fusion Inhibitors). For a description of the life-cycle of the AIDS virus, and the targets of each class of drugs, click here.

PRO 140 is being developed by Progenics Pharmaceuticals, Inc. They have a useful web site that includes the latest news & research reports on this and other drugs in development: click here.

AIDS drugs chartOur quick-reference chart allows you to compare all the currently available anti-HIV drugs, including dosing, side effects, & dietary restrictions.
news Treatment News
Search for recent news and archived stories about PRO 140.
forumsHave more questions? Then post a question or comment in our Community Forums.
Help Paying for MedsHelp Paying for Meds: Patient assistance and co-pay programs for HIV and viral hepatitis drugs.
Lessons Our Lessons: Check out our informative Lessons covering various topics to help you make treatment decisions.
Collapse All

Recommended Reading List:

Books about AIDS & HIV treatmentsFor a list of great books about living with HIV and making informed treatment decisions, along with easy links to buy them from, click here.

PRO 140


What is PRO 140?

  • PRO 140 is an experimental entry inhibitor being developed by Progenics Pharmaceuticals, Inc. It has not yet been evaluated by the U.S. Food and Drug Administration (FDA) for use by people living with HIV.
  • PRO 140 contains genetically engineered antibodies, known as monoclonal antibodies. These antibodies bind to the CCR5 coreceptor on CD4 cells (T cells). Once they do this, HIV cannot successfully bind with the surface of these cells, thus preventing the virus from infecting them.
  • PRO 140 will most likely need to be used in combination with other HIV drugs.

What is already known about PRO 140?
  • A dose for PRO 140 has not yet been determined. The drug has been administered intravenously, using a dose that depends on body weigh and by subcutaneous injection.
  • PRO 140 holds promise for HIV-positive patients who no longer respond to other HIV drugs. Because PRO 140 targets HIV differently than most currently available drugs, chances are that most people living with the virus—regardless of which drugs they have tried (and failed) in the past—will likely benefit from using PRO 140.
  • It is not known how quickly resistance to PRO 140 develops if resistance does occur.
  • PRO 140 might interact with other medications, including those used to treat HIV. It is important that your personal physician and/or the research nurse or study investigator be aware of all drugs you are taking, including those you buy without a prescription.
  • A Phase II study has been completed showing that PRO 140 can lower virus levels in the blood. Further trials looking at the safety and effectiveness of PRO 140 against HIV are planned or ongoing.

What about drug interactions?
  • No studies have yet reported whether PRO 140 may interact with other drugs. Trials to determine potential drug interactions are planned or ongoing.

What is known about side effects?
  • Information regarding the safety and possible side effects of PRO 140 in HIV-positive people has not yet ben reported. Studies to determine the potential side effects of PRO 140 are planned or ongoing.

Who should not take PRO 140?
  • It is not known whether PRO 140 will harm an unborn baby. It is very important to treat HIV/AIDS during pregnancy to reduce the risk of infecting your baby. Talk to your doctor about your treatment options.
  • It is not known whether PRO 140 passes into breast milk and what effect it may have on a nursing baby. To prevent transmission of the virus to uninfected babies, it is recommended that HIV-positive mothers not breast-feed.

Where can I learn more about clinical trials of PRO 140?
  • If you would like to find out if you are eligible for any clinical trials that include PRO 140, visit, a site run by the U.S. National Institutes of Health. The site has information about all HIV-related clinical studies in the United States. For more info, you can call their toll-free number at 1-800-HIV-0440 (1-800-448-0440) or email

Last Revised: January 30, 2009

This content is written by the POZ and AIDSmeds editorial team. For more information, please visit our "About Us" page.

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.